{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T14:16:34Z","timestamp":1795097794490,"version":"4.10.3"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Fabry disease (FD) is a rare, X-linked lysosomal deposition disease characterized by multi-system symptoms. The accumulation of globotriaosylceramide in various organs, such as the kidneys and heart, as well as the nervous system, has been speculated to be the mechanism involved in tissue damage, including vascular impairment with thrombotic events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Here, we describe a 72-year-old male patient diagnosed with FD, who first presented with acute myocardial infarction, left ventricular thrombosis, and pericardial effusion, accompanied by cardiac hypertrophy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>A physical examination showed that he was hemodynamically stable and an electrocardiogram showed ventricular tachycardia (Fig. 1A). The single obvious abnormality was an ST segment depression with a preterminal negative T wave in leads I and aVL (Fig. 1B). Coronary angiography revealed regular findings (Fig. 2). Echocardiogram conducted at our hospital revealed hypertrophy, ejection fraction 40%, pericardial effusion (Fig. 3). Speckle tracking two-dimensional echocardiography strain analysis technology confirmed left ventricular thrombosis, and also revealed decreased movement of the inferior and posterior walls, the basal segment of the posterior wall was locally fibrotic (Fig. 4A and B). Further, myocardial contrast echocardiography confirmed left ventricular thrombosis (Fig. 4C). Cardiovascular magnetic resonance imaging indicated biventricular uneven hypertrophy, which was considered metabolic cardiomyopathy, with diffuse fibrosis of biventricular walls, apical thrombosis, and ischemic cardiomyopathy in the basal segment of the left ventricular lateral wall and left ventricular anterior wall (Fig. 5). Serum alpha-galactosidase concentration was 0.7 nmol\/h\/mgPr (normal range, 29.0\u201364.4 nmol\/h\/mgPr). Subsequent genetic testing revealed that he was hemizygous for a previously reported missense mutation (c.902G&gt;A) inexon 6 of the <jats:italic toggle=\"yes\">GLA<\/jats:italic> gene,\n                                    <jats:sup>[1]<\/jats:sup>\n                                  which induce p.R301Q (p.Arg301Gln), confirming a diagnosis of FD (Fig. 6).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Orally administered drugs included rivaroxaban, sacubitril valsartan, beta blockers, dapagliflozin, and mineralocorticoid receptor antagonist. Cardiac resynchronization therapy with an implanted defibrillator was implemented to prevent sudden death.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>At present, he is still in follow-up and there have been no adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our case suggests that clinicians should consider the possibility of FD in patients with acute myocardial infarction and cardiomyopathy. A detailed analysis of subtle historical clues would help promote earlier diagnosis of FD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029427","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T21:04:03Z","timestamp":1653685443000},"page":"e29427","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Fabry disease with acute myocardial infarction, left ventricular thrombosis, and pericardial effusion"],"prefix":"10.1097","volume":"101","author":[{"given":"Shanshan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s100380170088","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype","volume":"46","author":"Ashley","year":"2001","journal-title":"J Hum Genet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/S0365-05962009000400008","article-title":"Fabry disease","volume":"84","author":"Boggio","year":"2009","journal-title":"An Bras Dermatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-4-21","article-title":"Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring","volume":"4","author":"Hoffmann","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/jcm10102160","article-title":"High prevalence of late-onset Fabry cardiomyopathy in a cohort of 499 non-selective patients with left ventricular hypertrophy: the Asian Fabry cardiomyopathy high-risk screening study (ASIAN-FAME)","volume":"10","author":"Fan","year":"2021","journal-title":"J Clin Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0000000000001333","article-title":"Thromboembolic events in Fabry disease and the impact of factor V Leiden","volume":"84","author":"Lenders","year":"2015","journal-title":"Neurology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e20190096","DOI":"10.1590\/1677-5449.190096","article-title":"Recurrent arterial thrombosis in a patient with Fabry disease: case report","volume":"19","author":"Moraes","year":"2020","journal-title":"J Vasc Bras"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.3390\/jcm10194422","article-title":"Atherosclerosis in Fabry disease \u2013 a contemporary review","volume":"10","author":"Roy","year":"2021","journal-title":"J Clin Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.amjcard.2019.05.009","article-title":"Efficacy of direct acting oral anticoagulants in treatment of left ventricular thrombus","volume":"124","author":"Fleddermann","year":"2019","journal-title":"Am J Cardiol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"ytab407","DOI":"10.1093\/ehjcr\/ytab407","article-title":"Pericardial effusion in the course of Fabry disease cardiomyopathy: a case report","volume":"5","author":"Tsuruda","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.stemcr.2019.07.004","article-title":"A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology","volume":"13","author":"Birket","year":"2019","journal-title":"Stem Cell Rep"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/glycob\/cwy026","article-title":"Specific storage of glycoconjugates with terminal \u03b1-galactosyl moieties in the exocrine pancreas of Fabry disease patients with blood group B","volume":"28","author":"Rybov\u00e1","year":"2018","journal-title":"Glycobiology"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J Intern Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:07:35Z","timestamp":1746328055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029427"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":19,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029427","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"2022-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}